SCHEMBL693516

SCHEMBL693516

FC(F)(F)Oc1ccc(-c2cc3c[c]ccc3[nH]2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
MAPT P10636 2/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
SCN10A Q9Y5Y9 6/20 0.40
KCNH2 Q12809 4/20 0.40
SCN1A P35498 1/20 0.40
SCN5A Q14524 1/20 0.40
SCN9A Q15858 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN8A Q9UQD0 1/20 0.40
TRPA1 O75762 1/20 0.39
P2RY1 P47900 2/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
NPY5R Q15761 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL694758 0.81 CCNB2 (0.43) KDM4ENPC1RAB9AMAPTCASP3
SCHEMBL702063 0.81 RAB9A (0.65) KDM4ENPC1RAB9AMAPTCASP3
SCHEMBL29737280 0.81 RAB9A (0.65) KDM4ENPC1RAB9AMAPTCASP3
SCHEMBL695386 0.79 CYP1A1 (0.45) KDM4ENPC1RAB9AMAPTCASP3
SCHEMBL1459067 0.77 CYP19A1 (0.59) KDM4ENPC1RAB9AMAPTCASP3
SCHEMBL694898 0.75 NPC1 (0.63) KDM4ENPC1RAB9AMAPTCASP3
SCHEMBL6824765 0.74 KDM4E (0.56) KDM4ENPC1RAB9AMAPTCASP3
SCHEMBL6118327 0.74 KDM4E (0.66) KDM4ENPC1RAB9AMAPTCASP3
SCHEMBL22021633 0.73 NPY5R (0.51) KDM4ENPC1RAB9AMAPTCASP3
SCHEMBL694000 0.73 CYP1A1 (0.47) KDM4ENPC1RAB9AMAPTCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421848-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS Janssen Pharmaceutica N.V. (BE) 2012-02-29 EP claimed
WO-2010124119-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 WO claimed
EP-3197450-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-08-02 EP disclosed
WO-2016046130-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-03-31 WO disclosed
EP-2421825-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS Janssen Pharmaceutica N.V. (BE) 2012-02-29 EP disclosed
EP-2421848-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS Janssen Pharmaceutica N.V. (BE) 2012-02-29 EP disclosed
WO-2010124108-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 WO disclosed
WO-2010124119-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 WO disclosed